Literature DB >> 17768607

Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats.

Li-Yen Lee1, Wei-Yi Ong, Akhlaq A Farooqui, Jean-Marc Burgunder.   

Abstract

RATIONALE: High levels of calcium independent phospholipase A2 (iPLA2) are present in certain regions of the brain, including the cerebral cortex, striatum, and cerebellum (Ong et al. 2005).
OBJECTIVES: The present study was carried out to elucidate a possible role of the enzyme in the motor system.
METHODS: The selective iPLA2 inhibitor bromoenol lactone (BEL), the nonselective PLA2 inhibitor methyl arachidonyl fluorophosphonate (MAFP), and an antisense oligonucleotide were used to interfere with iPLA2 activity in various components of the motor system. Control animals received injections of carrier (phosphate buffered saline, PBS) at the same locations. The number of vacuous chewing movements (VCM) was counted from 1 to 14 days after injection.
RESULTS: Rats that received BEL and high-dose MAFP injections in the striatum, thalamus, and motor cortex, but not the cerebellum, showed significant increase in VCM, compared to those injected with PBS at these locations. BEL-induced VCM were blocked by intramuscular injections of the anticholinergic drug, benztropine. Increased VCM was also observed after intrastriatal injection of antisense oligonucleotide to iPLA2. The latter caused a decrease in striatal iPLA2 levels, confirming a role of decreased enzyme activity in the appearance of VCM.
CONCLUSIONS: These results suggest an important role for iPLA2 in the cortex-striatum-thalamus-cortex circuitry. It is postulated that VCM induced by iPLA2 inhibition may be a model of human parkinsonian tremor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768607     DOI: 10.1007/s00213-007-0912-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

Review 1.  Alternatives to levodopa in the initial treatment of early Parkinson's disease.

Authors:  Andrew Lees
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.

Authors:  M F Egan; Y Hurd; J Ferguson; S E Bachus; E H Hamid; T M Hyde
Journal:  Psychopharmacology (Berl)       Date:  1996-10       Impact factor: 4.530

3.  Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat.

Authors:  J D Salamone; M D Lalies; S L Channell; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase A(2) inhibitor in rat hippocampal slices.

Authors:  S Fujita; Y Ikegaya; M Nishikawa; N Nishiyama; N Matsuki
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+.

Authors:  Mikhail Strokin; Marina Sergeeva; Georg Reiser
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 6.  Tremulous jaw movements in rats: a model of parkinsonian tremor.

Authors:  J D Salamone; A J Mayorga; J T Trevitt; M S Cousins; A Conlan; A Nawab
Journal:  Prog Neurobiol       Date:  1998-12       Impact factor: 11.685

Review 7.  Phospholipase A2 (PLA2) enzymes in membrane trafficking: mediators of membrane shape and function.

Authors:  William J Brown; Kimberly Chambers; Anne Doody
Journal:  Traffic       Date:  2003-04       Impact factor: 6.215

Review 8.  Retinoic acid-mediated phospholipase A2 signaling in the nucleus.

Authors:  Akhlaq A Farooqui; Pierre Antony; Wei-Yi Ong; Lloyd A Horrocks; Louis Freysz
Journal:  Brain Res Brain Res Rev       Date:  2004-07

9.  Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.

Authors:  O A Andreassen; R J Ferrante; T O Aamo; M F Beal; H A Jørgensen
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 10.  Anticholinergics for symptomatic management of Parkinson's disease.

Authors:  R Katzenschlager; C Sampaio; J Costa; A Lees
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  4 in total

1.  Nanomolar vitamin E alpha-tocotrienol inhibits glutamate-induced activation of phospholipase A2 and causes neuroprotection.

Authors:  Savita Khanna; Narasimham L Parinandi; Sainath R Kotha; Sashwati Roy; Cameron Rink; Douglas Bibus; Chandan K Sen
Journal:  J Neurochem       Date:  2009-12-17       Impact factor: 5.372

2.  Role of calcium independent phospholipase A2 in maintaining mitochondrial membrane potential and preventing excessive exocytosis in PC12 cells.

Authors:  May-Thu Ma; Jin-Fei Yeo; Akhlaq A Farooqui; Wei-Yi Ong
Journal:  Neurochem Res       Date:  2010-11-30       Impact factor: 3.996

3.  iPLA2β knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology.

Authors:  Helene Blanchard; Ameer Y Taha; Yewon Cheon; Hyung-Wook Kim; John Turk; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2014-06-12       Impact factor: 3.996

Review 4.  Maintenance of synaptic stability requires calcium-independent phospholipase A₂ activity.

Authors:  Julie Allyson; Xiaoning Bi; Michel Baudry; Guy Massicotte
Journal:  Neural Plast       Date:  2012-05-20       Impact factor: 3.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.